Pascal Chastagner
YOU?
Author Swipe
View article: Childhood isolated C3d-positive AIHA: favorable prognosis but rare relapse or associated immunodeficiency
Childhood isolated C3d-positive AIHA: favorable prognosis but rare relapse or associated immunodeficiency Open
Autoimmune hemolytic anemia (AIHA) with an isolated C3d-positive direct antiglobulin test is a rare and understudied condition in children. It typically encompasses cold agglutinin syndrome and paroxysmal cold hemoglobinuria, both transien…
View article: Azathioprine or mycophenolate mofetil for pediatric autoimmune cytopenia: A propensity score-matched study
Azathioprine or mycophenolate mofetil for pediatric autoimmune cytopenia: A propensity score-matched study Open
Data on the immunosuppressants azathioprine (AZA) and mycophenolate mofetil (MMF) in autoimmune cytopenia (AIC) are limited, and no direct comparison exists. We analyzed the failure-free survival (FFS) (time from AZA/MMF initiation to anot…
View article: Long-term kidney complications in childhood leukemia survivors: a study from the Childhood and Adolescent Leukaemia (LEA) project
Long-term kidney complications in childhood leukemia survivors: a study from the Childhood and Adolescent Leukaemia (LEA) project Open
Acute leukaemias represent the 1st cause of cancer in children. Their prognosis has improved significantly due to remarkable advances in therapeutic management, despite the risk of long-term consequences, especially for patients who underw…
View article: Deciphering Natural Killer Cell Cytotoxicity Against Medulloblastoma in vitro and in vivo: Implications for Immunotherapy
Deciphering Natural Killer Cell Cytotoxicity Against Medulloblastoma in vitro and in vivo: Implications for Immunotherapy Open
Our study confirmed that NK cells possess both in vitro and in vivo cytotoxic activity against MB cells and are of interest for the development of immunotherapy.
View article: Fertility Assessment after Ovarian Transposition in Children and Young Women Treated for a Malignant Tumor
Fertility Assessment after Ovarian Transposition in Children and Young Women Treated for a Malignant Tumor Open
Ovarian transposition (OT) has been proposed as a protective measure against radiation-induced damage to ovarian function and fertility. Despite its historical use, limited research has focused on evaluating endocrine and exocrine ovarian …
View article: Pediatric refractory chronic immune thrombocytopenia: Identification, patients' characteristics, and outcome
Pediatric refractory chronic immune thrombocytopenia: Identification, patients' characteristics, and outcome Open
Refractory chronic immune thrombocytopenia (r‐cITP) is one of the most challenging situations in chronic immune thrombocytopenia (cITP). Pediatric r‐cITP is inconsistently defined in literature, contributing to the scarcity of data. Moreov…
View article: Educational outcomes in siblings of childhood leukemia survivors: Factors associated with school difficulties and comparison with general population
Educational outcomes in siblings of childhood leukemia survivors: Factors associated with school difficulties and comparison with general population Open
Background To investigate the educational outcomes of siblings of childhood leukemia survivors, explore determinants of school difficulties, and compare the rates of repeating grades between siblings and the general population. Methods A c…
View article: Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial Open
PURPOSE Outcomes for children with relapsed and refractory high-risk neuroblastoma (RR-HRNB) remain dismal. The BEACON Neuroblastoma trial (EudraCT 2012-000072-42) evaluated three backbone chemotherapy regimens and the addition of the anti…
View article: A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors
A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors Open
Pediatric patients with recurrent and refractory cancers are in most need for new treatments. This study developed patient-derived-xenograft (PDX) models within the European MAPPYACTS cancer precision medicine trial (NCT02613962). To date,…
View article: Measuring Safety and Outcomes for the Use of Compassionate and Off-Label Therapies for Children, Adolescents, and Young Adults With Cancer in the SACHA-France Study
Measuring Safety and Outcomes for the Use of Compassionate and Off-Label Therapies for Children, Adolescents, and Young Adults With Cancer in the SACHA-France Study Open
Importance Innovative anticancer therapies for children, adolescents, and young adults are regularly prescribed outside their marketing authorization or through compassionate use programs. However, no clinical data of these prescriptions i…
View article: Age‐related immune cell dynamics influence outcomes after allogeneic haematopoietic cell transplantation
Age‐related immune cell dynamics influence outcomes after allogeneic haematopoietic cell transplantation Open
Summary An efficient immunological reconstitution construes the pillar for the success of allogeneic haematopoietic cell transplantation (HCT) in haematological disorders. Factors influencing post‐transplant immune recovery have been large…
View article: Supplementary Table 2 from Deep Sequencing Reveals Occurrence of Subclonal <i>ALK</i> Mutations in Neuroblastoma at Diagnosis
Supplementary Table 2 from Deep Sequencing Reveals Occurrence of Subclonal <i>ALK</i> Mutations in Neuroblastoma at Diagnosis Open
Supplementary Table 2. Primer sequences used for the amplification of ALK regions of interested in the first PCR-step
View article: Supplementary Figure 2 from Deep Sequencing Reveals Occurrence of Subclonal <i>ALK</i> Mutations in Neuroblastoma at Diagnosis
Supplementary Figure 2 from Deep Sequencing Reveals Occurrence of Subclonal <i>ALK</i> Mutations in Neuroblastoma at Diagnosis Open
Supplementary Figure 2. Comparison of polymorphism rs3738868 allele fractions located within the intronic region between exon 25 and exon 26 (position chr2:29432625) between the first deep sequencing and validation experiment. The 263 neur…
View article: Supplementary Figure 2 from Deep Sequencing Reveals Occurrence of Subclonal <i>ALK</i> Mutations in Neuroblastoma at Diagnosis
Supplementary Figure 2 from Deep Sequencing Reveals Occurrence of Subclonal <i>ALK</i> Mutations in Neuroblastoma at Diagnosis Open
Supplementary Figure 2. Comparison of polymorphism rs3738868 allele fractions located within the intronic region between exon 25 and exon 26 (position chr2:29432625) between the first deep sequencing and validation experiment. The 263 neur…
View article: Data from Deep Sequencing Reveals Occurrence of Subclonal <i>ALK</i> Mutations in Neuroblastoma at Diagnosis
Data from Deep Sequencing Reveals Occurrence of Subclonal <i>ALK</i> Mutations in Neuroblastoma at Diagnosis Open
Purpose: In neuroblastoma, activating ALK receptor tyrosine kinase point mutations play a major role in oncogenesis. We explored the potential occurrence of ALK mutations at a subclonal level using targeted deep sequencing.Experimental Des…
View article: Data from Deep Sequencing Reveals Occurrence of Subclonal <i>ALK</i> Mutations in Neuroblastoma at Diagnosis
Data from Deep Sequencing Reveals Occurrence of Subclonal <i>ALK</i> Mutations in Neuroblastoma at Diagnosis Open
Purpose: In neuroblastoma, activating ALK receptor tyrosine kinase point mutations play a major role in oncogenesis. We explored the potential occurrence of ALK mutations at a subclonal level using targeted deep sequencing.Experimental Des…
View article: Supplementary Table 1 from Deep Sequencing Reveals Occurrence of Subclonal <i>ALK</i> Mutations in Neuroblastoma at Diagnosis
Supplementary Table 1 from Deep Sequencing Reveals Occurrence of Subclonal <i>ALK</i> Mutations in Neuroblastoma at Diagnosis Open
Supplementary Table 1. Clinical and tumor genetic data of studied cohort of 276 NB patients
View article: supplemental figure legend from Deep Sequencing Reveals Occurrence of Subclonal <i>ALK</i> Mutations in Neuroblastoma at Diagnosis
supplemental figure legend from Deep Sequencing Reveals Occurrence of Subclonal <i>ALK</i> Mutations in Neuroblastoma at Diagnosis Open
supplemental figure legend. supplemental figure legend
View article: supplemental figure legend from Deep Sequencing Reveals Occurrence of Subclonal <i>ALK</i> Mutations in Neuroblastoma at Diagnosis
supplemental figure legend from Deep Sequencing Reveals Occurrence of Subclonal <i>ALK</i> Mutations in Neuroblastoma at Diagnosis Open
supplemental figure legend. supplemental figure legend
View article: Supplementary Table 2 from Deep Sequencing Reveals Occurrence of Subclonal <i>ALK</i> Mutations in Neuroblastoma at Diagnosis
Supplementary Table 2 from Deep Sequencing Reveals Occurrence of Subclonal <i>ALK</i> Mutations in Neuroblastoma at Diagnosis Open
Supplementary Table 2. Primer sequences used for the amplification of ALK regions of interested in the first PCR-step
View article: Supplementary Figure 1 from Deep Sequencing Reveals Occurrence of Subclonal <i>ALK</i> Mutations in Neuroblastoma at Diagnosis
Supplementary Figure 1 from Deep Sequencing Reveals Occurrence of Subclonal <i>ALK</i> Mutations in Neuroblastoma at Diagnosis Open
Supplementary Figure 1. Background variability observed by high coverage Hiseq2500 Illumina® sequencing in 24 germline DNA controls.
View article: Supplementary Figure 1 from Deep Sequencing Reveals Occurrence of Subclonal <i>ALK</i> Mutations in Neuroblastoma at Diagnosis
Supplementary Figure 1 from Deep Sequencing Reveals Occurrence of Subclonal <i>ALK</i> Mutations in Neuroblastoma at Diagnosis Open
Supplementary Figure 1. Background variability observed by high coverage Hiseq2500 Illumina® sequencing in 24 germline DNA controls.
View article: Supplementary Table 1 from Deep Sequencing Reveals Occurrence of Subclonal <i>ALK</i> Mutations in Neuroblastoma at Diagnosis
Supplementary Table 1 from Deep Sequencing Reveals Occurrence of Subclonal <i>ALK</i> Mutations in Neuroblastoma at Diagnosis Open
Supplementary Table 1. Clinical and tumor genetic data of studied cohort of 276 NB patients
View article: Supplementary Table 3 from Integrin α5β1 Plays a Critical Role in Resistance to Temozolomide by Interfering with the p53 Pathway in High-Grade Glioma
Supplementary Table 3 from Integrin α5β1 Plays a Critical Role in Resistance to Temozolomide by Interfering with the p53 Pathway in High-Grade Glioma Open
PDF file - 27K, Relationship between Alpha5 mRNA level and p53 status in human biopsies and in human xenografts in nude mice
View article: Supplementary Figure 1 from Integrin α5β1 Plays a Critical Role in Resistance to Temozolomide by Interfering with the p53 Pathway in High-Grade Glioma
Supplementary Figure 1 from Integrin α5β1 Plays a Critical Role in Resistance to Temozolomide by Interfering with the p53 Pathway in High-Grade Glioma Open
PDF file - 131K, The effect of Alpha5 integrin on p53 activity and resistance to temozolomide is restricted to p53wt expressing cells
View article: Supplementary Table 2 from Integrin α5β1 Plays a Critical Role in Resistance to Temozolomide by Interfering with the p53 Pathway in High-Grade Glioma
Supplementary Table 2 from Integrin α5β1 Plays a Critical Role in Resistance to Temozolomide by Interfering with the p53 Pathway in High-Grade Glioma Open
PDF file - 23K, Proportion of grade III and grade IV glioma in the subgroups of patients with high and low Alpha5 integrin mRNA expression in the 3 cohorts of patients included in this study
View article: Supplementary Figure 1 from Integrin α5β1 Plays a Critical Role in Resistance to Temozolomide by Interfering with the p53 Pathway in High-Grade Glioma
Supplementary Figure 1 from Integrin α5β1 Plays a Critical Role in Resistance to Temozolomide by Interfering with the p53 Pathway in High-Grade Glioma Open
PDF file - 131K, The effect of Alpha5 integrin on p53 activity and resistance to temozolomide is restricted to p53wt expressing cells